Meeting on the Mesa 2021 | The future landscape of gene therapies

Devyn Smith, PhD, Arbor Biotechnologies, Cambridge, MA, outlines his opinions on how the gene therapy sector can advance. Whilst there are a small number of gene therapies that have been approved, future development needs to focus on increased durability of the treatments. Dr Smith additionally focuses on streamlining the manufacturing of gene therapies to enable commercialization, as well as novel delivery systems including synthetic vectors and nanoparticles to target more cell types. This interview took place at Meeting on the Mesa 2021.